By Sarah Carqueville, Product Manager CellGenix GMP Media
Cell and gene therapies, including T cell therapy, have become a promising approach for treating various diseases. However, the successful manufacturing of these therapies requires overcoming operational challenges associated with novel and emerging modalities. Specifically, the manufacturing process of T cell products, such as CAR T cells, must yield a sufficient number of cells with defined properties within a reasonable timeframe.
This study shows that enhanced T cell expansion as well as the generation of an early-differentiated phenotype can be achieved using CellGenix® reagents, a cell culture medium for T cells and cytokines, in a static bioreactor system, G-Rex®. Notably, these reagents are serum-free, and there is no need to add serum. This minimizes serum-associated risks and eliminates variability in the manufacturing process. Explore how T cell culture in CellGenix® GMP TCM effectively supports the expansion of CD8+ and CD4+ T cells within the G-Rex® bioreactor system.